Investment Rating - The investment rating for the company is "Buy" with initial coverage [1] Core Insights - The company reported stable revenue growth in Q3 2025, with a total revenue of 610 million yuan, representing a 2.6% increase year-on-year. The net profit attributable to shareholders was 90 million yuan, up 20.9% year-on-year [4][5] - The gross margin improved significantly in Q3 2025, reaching 29.1%, an increase of 8.3 percentage points compared to the previous year. The net profit margin for Q3 was 15.2%, up 6.5 percentage points year-on-year [6] - The company is a leading player in the domestic SMO industry, with expectations for further recovery in the innovative drug financing market by 2026. Revenue forecasts for 2025, 2026, and 2027 are 830 million, 950 million, and 1.03 billion yuan, respectively, with corresponding net profits of 120 million, 160 million, and 180 million yuan [7] Company Overview - The latest closing price of the company's stock is 56.80 yuan, with a total market capitalization of 4.5 billion yuan. The company has a total share capital of 79 million shares, with 75 million shares in circulation. The highest and lowest prices in the last 52 weeks were 56.80 yuan and 24.84 yuan, respectively [3]

Group 1 - The core point of the news is that Prasis (Shanghai) Pharmaceutical Technology Development Co., Ltd. experienced a stock price increase of 5.56%, reaching 57.00 CNY per share, with a total market capitalization of 4.503 billion CNY as of January 7 [1] - The company, established on February 22, 2013, and listed on May 17, 2022, focuses on technology development, transfer, consultation, and services in the pharmaceutical sector, with 100% of its revenue coming from services [1] Group 2 - From the perspective of fund holdings, the Chuangjin Hexin Fund has a significant position in Prasis, with its Chuangjin Hexin Health Mixed A Fund (013348) holding 121,000 shares, representing 4.56% of the fund's net value, making it the tenth largest holding [2] - The Chuangjin Hexin Health Mixed A Fund was established on January 26, 2022, with a current scale of 47.4529 million CNY, and has achieved a year-to-date return of 5.36%, ranking 833 out of 8,823 in its category [2] Group 3 - The fund manager of Chuangjin Hexin Health Mixed A Fund is Pi Jinsong, who has been in the position for 7 years and 71 days, managing assets totaling 900 million CNY, with the best fund return during his tenure being 92.69% and the worst being -49.36% [3]

Group 1 - The company, Pruis (301257), reported that as of December 31, 2025, the total number of shareholders will be 6,759 [1]

证券日报网讯 1月5日，普蕊斯在互动平台回答投资者提问时表示，截至2025年12月31日收盘，公司股 东总数为6759户。 （文章来源：证券日报） ...

Group 1 - The core investment theme for the pharmaceutical industry in 2025 is the overseas expansion of innovative drugs, which is expected to yield excess returns compared to the broader pharmaceutical sector and the CSI 300 index [2][21] - The innovative drug index has shown a significant increase, outperforming the pharmaceutical biological index by 37.48 percentage points, with a year-to-date increase of 65.99% [21] - Major transactions in the ADC and dual antibody fields are anticipated to continue, while there is a need to avoid repetitive competition in areas like small nucleic acids and focus on unmet clinical needs [3][4] Group 2 - The report emphasizes the importance of overseas markets for both innovative drugs and medical devices, suggesting that companies should seek growth opportunities beyond domestic market saturation [4][5] - The Chinese pharmaceutical industry is gradually becoming a global innovation center, with significant advancements in dual antibodies and ADCs, while also making strides in emerging fields like small nucleic acids and inhalation formulations [5][6] - The report highlights that the overseas authorization revenue has become a crucial funding source for innovative drug development, with a total upfront payment of $4.551 billion in the first three quarters of 2025 [29][32] Group 3 - The medical device sector is experiencing a shift towards overseas expansion, with a focus on high-value consumables and IVD products, as Chinese companies enhance their market share [7][55] - The export growth of high-value consumables is significant, with a recorded increase of 10.75% in the first half of 2025, particularly in the North American and European markets [57][66] - The report notes that the certification and market establishment processes for high-value consumables are long-term investments, requiring compliance with stringent regulations in the EU and the US [60][61] Group 4 - The recovery of financing in the domestic innovative drug sector has been robust, with a total of 324 financing events amounting to $5.51 billion in the first three quarters of 2025, marking a 67.6% increase year-on-year [70][72] - The CXO industry is experiencing varied recovery rhythms across different segments, with some areas like CDMO seeing order growth due to overseas financing recovery [74]

Company Overview - Proris is a big data-driven clinical research service provider focused on creating a comprehensive project management system for clinical trials, emphasizing a patient-centered approach [1][2] - As of Q3 2025, the company achieved a revenue of CNY 219 million, representing a year-on-year growth of 9.84% [2] - The net profit for Q3 2025 was CNY 69.67 million, a significant increase of 120.72% compared to the previous year [2] Financial Performance - For the first three quarters of 2025, the total revenue reached CNY 609 million, with a year-on-year growth of 2.59% [2] - The net profit for the first three quarters was CNY 67.67 million, reflecting an 11.48% increase year-on-year [2] - The company distributed cash dividends totaling CNY 5.37 million in 2025, demonstrating a commitment to shareholder returns [4] Market Position and Competitive Landscape - The SMO industry is experiencing a concentration of resources towards leading firms, with increased competition characterized by: - Leading SMO companies expanding their client resources, professional talent, and research coverage [3] - Smaller SMOs gradually exiting the market, leading to increased industry concentration [3] - Proris has established partnerships with major global pharmaceutical companies and CROs, enhancing its service capabilities in innovative drug projects [4] Project Execution and Areas of Expertise - As of September 2025, Proris has undertaken over 4,200 clinical projects, with 2,538 currently in execution, covering various disease areas including hematological tumors, solid tumors, and rare diseases [4] - The company has a competitive advantage in several therapeutic areas, including cardiovascular diseases and endocrine disorders [4] Digital Transformation and Efficiency - Proris is focused on integrating digital technologies into its operations to enhance efficiency and service quality [6] - The company has developed a robust quality management system that supports cost reduction and efficiency improvements [4][6]

Investment Rating - The report indicates a positive outlook for the SMO industry, suggesting it is entering a new growth cycle [15]. Core Insights - The SMO industry is experiencing steady growth driven by an increase in clinical trial registrations, particularly for innovative drugs, with a projected market size of 35 billion yuan by 2030 [23]. - The report highlights the recovery of the innovative drug sector, with an emphasis on the importance of quality over quantity in drug development [9]. - The medical device sector is benefiting from a rebound in bidding activities and government subsidies for home medical devices, indicating a favorable investment environment [56]. Summary by Sections Market Review - The report notes a slight decline in the CITIC pharmaceutical index, underperforming the CSI 300 index by 2.14 percentage points, ranking 26th among 30 primary industries [6]. Industry and Stock Events - The report identifies key stocks that have performed well, including Hongyuan Pharmaceutical and Luyan Pharmaceutical, while also noting significant declines in stocks like ST Bailing and Huaren Health [6]. Overall Viewpoint and Investment Themes - The report emphasizes the transition in the innovative drug sector from quantity to quality, recommending companies such as BeiGene and Innovent Biologics for their potential to deliver profits [9]. - In the medical device sector, the report highlights the recovery in imaging equipment procurement and the growth of home medical devices, recommending companies like Mindray and Yuyue Medical [9]. - The report discusses the potential for the CXO and life sciences services sector to recover, with a focus on companies that can leverage their market position for high-profit returns [9]. - The report suggests that the pharmaceutical industry is entering a new growth cycle, particularly in the specialty raw materials sector, with companies like Tonghua Dongbao and Huahai Pharmaceutical recommended for investment [9]. SMO Industry Insights - The SMO industry is characterized by a stable growth trajectory, with a significant increase in clinical trial registrations, particularly in complex therapeutic areas [23]. - The report notes that the demand for SMO services is expected to rise as the number of innovative drug trials increases, with a forecasted annual registration of 4,900 clinical trials in 2024, representing a 13.9% year-on-year growth [23]. - The report highlights the potential for AI applications to enhance efficiency and reduce costs in the SMO sector, which traditionally relies heavily on manual processes [33]. Medical Services and Pharmacy - The report expresses optimism about the pharmacy sector, driven by the acceleration of prescription outflow and the optimization of competitive dynamics, recommending companies like YaoXing and YiFeng Pharmacy [61]. - In the medical services sector, the report highlights the potential for private healthcare providers to enhance their competitive edge through reforms and the expansion of commercial insurance [63].

（编辑 姚尧） 证券日报网讯 12月17日晚间，普蕊斯发布公告称，普蕊斯（上海）医药科技开发股份有限公司（以下 简称"公司"）于2025年11月19日披露了《关于公司股东减持股份预披露公告》，公司股东淄博弘润盈科 创业投资合伙企业（有限合伙）（曾用名：平潭弘润盈科新材料创业投资合伙企业（有限合伙）、福州 弘润盈科新材料创业投资中心（有限合伙），以下简称"弘润盈科"）、股东石河子市睿新股权投资合伙 企业（有限合伙）（以下简称"石河子睿新"）和财务总监宋卫红计划自减持计划公告发布之日起15个交 易日后的3个月内以集中竞价交易方式分别减持本公司股份不超过6，500股（占本公司总股本比例 0.0082%）、73，100股（占本公司总股本比例0.0925%）、800股（占本公司总股本比例0.0010%）。近 日，公司收到股东弘润盈科、石河子睿新和财务总监宋卫红女士分别出具的《关于股份减持计划实施完 成的告知函》，截至本公告披露日，上述股东的减持计划已实施完成。 ...

Group 1 - The core point of the article is that the company, Puris (SZ 301257), announced the completion of a share reduction plan by its shareholders, resulting in a total reduction of approximately 80,400 shares [1] - The shareholders involved in the reduction plan include Hongrun Yinke, Shihezi Ruixin, and the financial director, Ms. Song Weihong [1] - As of the announcement date, the company's revenue composition for the first half of 2025 is entirely from the service industry, accounting for 100% [1] Group 2 - The current market capitalization of Puris is 3.6 billion yuan [2]

证券代码：301257 证券简称：普蕊斯 公告编号：2025-070 近日，公司收到股东弘润盈科、石河子睿新和财务总监宋卫红女士分别出具 的《关于股份减持计划实施完成的告知函》，截至本公告披露日，上述股东的减 持计划已实施完成。根据《证券法》《上市公司股东减持股份管理暂行办法》《深 圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《深圳证券交易所上市公司自律监管指引第 18 号——股东及董事、高级管理人员减持股份》等相关规定，现将相关情况公 告如下： 一、股东减持计划实施情况 普蕊斯（上海）医药科技开发股份有限公司 关于公司股东减持计划实施完成的公告 公司股东淄博弘润盈科创业投资合伙企业（有限合伙）、股东石河子市睿 新股权投资合伙企业（有限合伙）和财务总监宋卫红女士保证向本公司提供的 信息内容真实、准确、完整、没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 普蕊斯（上海）医药科技开发股份有限公司（以下简称"公司"）于 2025 年 11 月 19 日披露了《关于公司 ...